Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: Am J Prev Med. 2018 Dec 17;56(2):196–204. doi: 10.1016/j.amepre.2018.09.020

Table 2.

Expected Values of Base Case Cost Effectiveness Comparing Universal MenB Vaccination for College Students to Standard of Care

EV cost (US$, 2015) Incremental EV cost EV effectiveness (QALYs) Incremental EV effectiveness ICER ($/QALYs) Cost per case averted
Health sector perspective
    Universal vaccination 324.25 299.53 25.89998 0.0000215 13,899,861 65,116,255
    Standard of care 24.72 25.89996
Societal perspective
    Universal vaccination 325.55 298.24 25.89998 0.0000215 13,839,796 64,834,867
    Standard of care 27.31 25.89996

EV, estimated value; QALYs, quality adjusted life years; ICER, incremental cost-effectiveness ratio; Men B, Neisseria meningitidis serogroup B.